Inmune Bio Files 8-K Report
Ticker: INMB · Form: 8-K · Filed: Feb 12, 2025 · CIK: 1711754
| Field | Detail |
|---|---|
| Company | Inmune Bio, Inc. (INMB) |
| Form Type | 8-K |
| Filed Date | Feb 12, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, financials
Related Tickers: INMB
TL;DR
INMB filed an 8-K. Check for updates on financials and events.
AI Summary
On February 12, 2025, Inmune Bio, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and operational events. No specific new financial figures or material events were detailed in the provided excerpt.
Why It Matters
This filing serves as an official notification to investors and the public about significant company events or financial updates, providing transparency into Inmune Bio's operations.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing notification without specific material events or financial disclosures that would indicate immediate risk.
Key Players & Entities
- Inmune Bio, Inc. (company) — Registrant
- February 12, 2025 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
- 001-38793 (identifier) — Commission File Number
- 47-5205835 (identifier) — IRS Employer Identification No.
- 225 NE Mizner Blvd. , Suite 640 , Boca Raton , Florida 33432 (address) — Address of Principal Executive Offices
- 858-964-3720 (phone_number) — Registrant's Telephone Number
FAQ
What specific "Other Events" are being reported by Inmune Bio, Inc. in this 8-K filing?
The provided excerpt does not detail the specific "Other Events" being reported; it only lists the item category.
What is the significance of the "Financial Statements and Exhibits" item listed in the filing?
This indicates that the filing includes or updates financial statements and other exhibits, which could contain important financial information about the company.
When was the earliest event reported in this Form 8-K?
The earliest event reported is dated February 12, 2025.
What is Inmune Bio, Inc.'s state of incorporation and IRS Employer Identification Number?
Inmune Bio, Inc. is incorporated in Nevada and its IRS Employer Identification Number is 47-5205835.
Where are Inmune Bio, Inc.'s principal executive offices located?
The principal executive offices are located at 225 NE Mizner Blvd., Suite 640, Boca Raton, Florida 33432.
Filing Stats: 476 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2025-02-12 16:00:37
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per shares INMB The NASDAQ Stock Ma
Filing Documents
- ea0230833-8k_inmune.htm (8-K) — 23KB
- ea023083301ex99-1_inmune.htm (EX-99.1) — 12KB
- ex99-1_001.jpg (GRAPHIC) — 5KB
- 0001213900-25-012870.txt ( ) — 215KB
- inmb-20250212.xsd (EX-101.SCH) — 3KB
- inmb-20250212_lab.xml (EX-101.LAB) — 33KB
- inmb-20250212_pre.xml (EX-101.PRE) — 22KB
- ea0230833-8k_inmune_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. On February 12, 2025, INmune Bio Inc. (the "Company"), issued a press release announcing the completion of the third and highest dose cohort of the Phase I portion of the Company's natural killer cell therapy, INKmune, in a Phase I/II trial for men with metastatic castration-resistant prostate cancer, allowing opening of the Phase II high dose cohort. A copy of the Company's press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Financial statements and Exhibits
Item 9.01 Financial statements and Exhibits (d) Exhibits. 99.1 Press Release dated February 12, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMUNE BIO INC. Date: February 12, 2025 By: /s/ David Moss Name: David Moss Title: Chief Financial Officer 2